A leading provider of
innovative DNA Screening solutions
PDGFB Breakapart Probe LPH031
Some cases of CML have constitutive activation of the gene for PDGFRβ which encodes a receptor for tyrosine kinase. The activation is usually caused by a t(5;12)(q32;p13) translocation which results in the ETV6-PDGFRβ fusion gene. The drug imatinib mesylate (Gleevec) specifically inhibits the kinase activity of PDGFRβ and has shown efficiency in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours.
PDGFRB Breakapart Probe
Cat. No. LPH 031-S (5 tests)
Cat. No. LPH 031 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK